These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17428846)

  • 21. Viral cell recognition and entry.
    Rossmann MG
    Protein Sci; 1994 Oct; 3(10):1712-25. PubMed ID: 7849588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structures of poliovirus complexes with anti-viral drugs: implications for viral stability and drug design.
    Grant RA; Hiremath CN; Filman DJ; Syed R; Andries K; Hogle JM
    Curr Biol; 1994 Sep; 4(9):784-97. PubMed ID: 7820548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel basis of capsid stabilization by antiviral compounds.
    Phelps DK; Post CB
    J Mol Biol; 1995 Dec; 254(4):544-51. PubMed ID: 7500332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SDZ 35-682, a new picornavirus capsid-binding agent with potent antiviral activity.
    Rosenwirth B; Oren DA; Arnold E; Kis ZL; Eggers HJ
    Antiviral Res; 1995 Jan; 26(1):65-82. PubMed ID: 7741522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SCH 38057: a picornavirus capsid-binding molecule with antiviral activity after the initial stage of viral uncoating.
    Rozhon E; Cox S; Buontempo P; O'Connell J; Slater W; De Martino J; Schwartz J; Miller G; Arnold E; Zhang A
    Antiviral Res; 1993 May; 21(1):15-35. PubMed ID: 8391247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low temperature and pressure stability of picornaviruses: implications for virus uncoating.
    Oliveira AC; Ishimaru D; Gonçalves RB; Smith TJ; Mason P; Sá-Carvalho D; Silva JL
    Biophys J; 1999 Mar; 76(3):1270-9. PubMed ID: 10049311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distinct cellular receptor interactions in poliovirus and rhinoviruses.
    Xing L; Tjarnlund K; Lindqvist B; Kaplan GG; Feigelstock D; Cheng RH; Casasnovas JM
    EMBO J; 2000 Mar; 19(6):1207-16. PubMed ID: 10716921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of an antiviral compound on the temperature dependence of viral protein flexibility and packing: a molecular dynamics study.
    Phelps DK; Rossky PJ; Post CB
    J Mol Biol; 1998 Feb; 276(2):331-7. PubMed ID: 9512706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure determination of antiviral compound SCH 38057 complexed with human rhinovirus 14.
    Zhang A; Nanni RG; Li T; Arnold GF; Oren DA; Jacobo-Molina A; Williams RL; Kamer G; Rubenstein DA; Li Y
    J Mol Biol; 1993 Apr; 230(3):857-67. PubMed ID: 8386772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural analysis of human rhinovirus complexed with ICAM-1 reveals the dynamics of receptor-mediated virus uncoating.
    Xing L; Casasnovas JM; Cheng RH
    J Virol; 2003 Jun; 77(11):6101-7. PubMed ID: 12743267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human rhinovirus HRV14 uncoats from early endosomes in the presence of bafilomycin.
    Bayer N; Prchla E; Schwab M; Blaas D; Fuchs R
    FEBS Lett; 1999 Dec; 463(1-2):175-8. PubMed ID: 10601662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating.
    Smith TJ; Kremer MJ; Luo M; Vriend G; Arnold E; Kamer G; Rossmann MG; McKinlay MA; Diana GD; Otto MJ
    Science; 1986 Sep; 233(4770):1286-93. PubMed ID: 3018924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the three-dimensional structure of two human rhinoviruses (HRV2 and HRV14).
    Blaas D; Kuechler E; Vriend G; Arnold E; Luo M; Rossmann MG
    Proteins; 1987; 2(4):263-72. PubMed ID: 2834716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug.
    Fox MP; Otto MJ; McKinlay MA
    Antimicrob Agents Chemother; 1986 Jul; 30(1):110-6. PubMed ID: 3019232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. H1PVAT is a novel and potent early-stage inhibitor of poliovirus replication that targets VP1.
    Tijsma A; Thibaut HJ; Spieser SA; De Palma A; Koukni M; Rhoden E; Oberste S; Pürstinger G; Volny-Luraghi A; Martin J; Marchand A; Chaltin P; Neyts J; Leyssen P
    Antiviral Res; 2014 Oct; 110():1-9. PubMed ID: 25043639
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Crystal structure of human rhinovirus serotype 1A (HRV1A).
    Kim SS; Smith TJ; Chapman MS; Rossmann MC; Pevear DC; Dutko FJ; Felock PJ; Diana GD; McKinlay MA
    J Mol Biol; 1989 Nov; 210(1):91-111. PubMed ID: 2555523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Binding affinities of structurally related human rhinovirus capsid-binding compounds are related to their activities against human rhinovirus type 14.
    Fox MP; McKinlay MA; Diana GD; Dutko FJ
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1040-7. PubMed ID: 1656851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of drug-resistance mutants to identify functional regions in picornavirus capsid proteins.
    Mosser AG; Shepard DA; Rueckert RR
    Arch Virol Suppl; 1994; 9():111-9. PubMed ID: 8032243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rhinovirus-mediated endosomal release of transfection complexes.
    Zauner W; Blaas D; Kuechler E; Wagner E
    J Virol; 1995 Feb; 69(2):1085-92. PubMed ID: 7815487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploitation of nuclear functions by human rhinovirus, a cytoplasmic RNA virus.
    Flather D; Nguyen JHC; Semler BL; Gershon PD
    PLoS Pathog; 2018 Aug; 14(8):e1007277. PubMed ID: 30142213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.